// App-Quantinova.ai

49 : Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.

Researchers

Presenter

  • David S. Hong

Principal Investigators

  • Geoffrey Shapiro

  • Andrea Varga

  • Aung Naing

  • Funda Meric-Bernstam

  • Larisa Reyderman

  • Xingfeng Bao

  • Terri A. Binder

  • Min Ren

  • Amy Siu

  • Lu Xu

  • Mingjie Liu

  • Satish Dayal

  • Vijay Bhagawati-Prasad

  • Ilian Tchakov

  • Takashi Owa

  • Chean Eng Ooi

  • Aurelien Marabelle

Medical Centers

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Massachusetts General Hospital, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Gustave Roussy Cancer Campus, Villejuif, France

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • 1.MD Anderson Cancer Center, Houston, TX

  • Eisai Inc, Woodcliff Lake, NJ

  • Eisai, Inc., Andover, MA

  • Eisai Ltd., Hatfield, United Kingdom

Locations

  • United States

  • France

  • United Kingdom

Companies

  • Eisai Inc.

  • Eisai Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Prostaglandin E2

Drug/Treatment

  • Dinoprostone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02540291

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved